AngioDynamics Announces American Medical Association’s CPT® Editorial Panel Grants Category I CPT® for Irreversible Electroporation (IRE) in Prostate and Liver
ANGO 10.21.2024
About Gravity Analytica
New Codes Expand Market Access to Treatment with the NanoKnife®System
The decision by the American Medical Association’s (“AMA”) CPT®
The NanoKnife System utilizes IRE technology to effectively destroy targeted cells without the use of thermal energy by delivering high-voltage pulses, creating permanent nanopores within the cell membrane. This minimally invasive treatment offers unique advantages over traditional surgery or thermal ablation techniques enabling physicians to treat all segments of an organ, with precise treatment margins, and a lower likelihood of side effects due to its preservation of nerve and blood vessel architecture.1,2,3
“Achieving CPT®Category I status is a significant milestone for the NanoKnife System and underscores our commitment to providing innovative and effective treatment options for patients,” said
With these new CPT®Category I codes, healthcare providers will be able to bill more precisely for the treatments provided and should achieve broader insurance coverage and defined reimbursement rates for NanoKnife procedures, increasing market access to this minimally invasive IRE technology.
The CPT®Category I codes are reserved for services and procedures that have demonstrated clinical efficacy, widespread use, and proven value in the medical community. The recognition of Irreversible Electroporation under these codes follows rigorous clinical studies and peer-reviewed data using the NanoKnife System that met the requirements for Category I CPT® codes.
About the NanoKnife System
The NanoKnife System utilizes Irreversible Electroporation (IRE) technology to effectively destroy targeted cells without the use of thermal energy by delivering high-voltage pulses, creating permanent nanopores within the cell membrane. This stimulus induces an apoptotic-like cellular death in the targeted tissue, resulting in a complete ablation of the targeted tissue.4Visitnanoknife.comfor full product information.
About
The Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visitwww.angiodynamics.com.
Safe Harbor
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “projects,” “optimistic,” or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics’ expectations, expressed or implied. Factors that may affect the actual results achieved by
In
______________________________1Faiella E, Santucci D, D'Amone G, et al. Focal minimally invasive treatment in localized prostate cancer: comprehensive review of different possible strategies.Cancers (
View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241017440579/en/
Investor Contact:
Media Contact:
Source: